Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims are not supported by the provided FDA label excerpts (notably indication claims for epilepsy/fibromyalgia/anxiety disorders), while some discontinuation/tapering and withdrawal-when-discontinued symptoms are partially aligned. Multiple withdrawal symptom items listed are not all supported by the label excerpt (5.6).
Category Scores
Accurate Statements
Lyrica is the brand name for pregabalin.
Label text identifies LYRICA (pregabalin) (e.g., 12.1 Mechanism of Action: “LYRICA (pregabalin) binds…”.)
When discontinuing LYRICA, taper gradually over a minimum of 1 week.
2.1 Important Administration Instructions: “When discontinuing LYRICA, taper gradually over a minimum of 1 week [see Warnings and Precautions (5.6)].”
Tapering off LYRICA should be done under the guidance of a healthcare professional.
Not explicitly stated as “under the guidance…”, but the label directs gradual withdrawal (5.6). (Marked as partially supported overall; not explicitly phrased in the excerpt.)
Withdrawal symptoms from pregabalin can include anxiety and insomnia.
5.6: “…abrupt or rapid discontinuation… insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea”.
Tapering off the medication gradually under the guidance of a healthcare professional can help reduce the severity of withdrawal symptoms.
5.6: “withdraw LYRICA gradually” and lists symptoms after abrupt/rapid discontinuation (implying gradual withdrawal reduces occurrence/severity vs abrupt/rapid).
Not tapering off Lyrica can lead to severe withdrawal symptoms, including seizures in severe cases.
5.6 supports withdrawal symptoms after abrupt/rapid discontinuation (but does not list seizures in the provided excerpt). Therefore this element is only partially supported. (See unsupported/contradiction below for specifics.)
Unsupported Statements
Pregabalin is prescribed to treat epilepsy.
The label excerpt supports adjunctive therapy for partial-onset seizures (2.4), not “epilepsy” generally.
Pregabalin is prescribed to treat anxiety disorders.
No indication for anxiety disorders is included in the provided Indications and Usage (1).
Withdrawal symptoms from pregabalin can include depression and mood swings.
5.6 (provided) lists insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea after abrupt/rapid discontinuation; depression/mood swings are not mentioned in the excerpt.
Withdrawal symptoms from pregabalin can include fatigue and lethargy.
5.6 (provided) does not list fatigue or lethargy as discontinuation symptoms.
Withdrawal symptoms from pregabalin can include headaches and migraines.
5.6 mentions “headache” but does not mention “migraines.” (Headaches are supported; migraines are not.)
Withdrawal symptoms from pregabalin can include nausea and vomiting.
5.6 mentions “nausea” but does not mention “vomiting.”
Withdrawal symptoms from pregabalin can include seizures in severe cases.
The provided 5.6 excerpt lists specific symptoms but does not mention seizures as discontinuation symptoms.
Tapering off pregabalin should involve a gradual reduction in dosage over a period of weeks or months to minimize withdrawal symptoms.
Label excerpt specifies taper gradually over a minimum of 1 week (2.1). It does not specify “weeks or months.”
Tapering off the medication gradually under the guidance of a healthcare professional can make the withdrawal process less painful.
5.6 does not address pain or “less painful.”
Support from a therapist or support group can reduce withdrawal symptoms and improve mental health outcomes in patients experiencing pregabalin withdrawal.
No such recommendation or claim appears in the provided label excerpts.
It is generally recommended to taper off Lyrica over a period of weeks or months.
Label excerpt only states taper gradually over a minimum of 1 week; it does not support “weeks or months” as a general recommendation.
It is not recommended to taper off Lyrica on your own.
The label excerpts provide taper/discontinuation guidance but do not explicitly state “not recommended… on your own.”
While other medications may be prescribed to manage withdrawal symptoms, new medications should be discussed with a healthcare professional before taking them.
No statement in the provided label excerpts discusses managing discontinuation symptoms with other medications or advice about discussing new medications.
Contradictions
Low
AI Statement
Pregabalin is prescribed to treat fibromyalgia.
Label Reference
Label does indicate LYRICA is indicated for management of fibromyalgia (1), so this is not a contradiction. No contradiction found for this item.
Important Omissions
Specific label-required taper detail (minimum of 1 week) was not fully reflected where the response states “weeks or months.”
Importance:
Moderate
Relevant discontinuation warning context that symptoms occur following abrupt/rapid discontinuation was not consistently paired with the specific label list of discontinuation symptoms (5.6).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several discontinuation symptom claims (e.g., seizures, vomiting, depression/mood swings, fatigue/lethargy, migraines) are not supported by the provided label excerpt. Also, taper timing specificity (“weeks or months”) and lack of explicit guidance phrasing could lead to incomplete adherence to label-described minimum taper duration (minimum of 1 week). Indication misstatements (anxiety disorders; general epilepsy) could also mislead use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Indication claims for epilepsy/anxiety disorders are not supported by provided label excerpts; multiple listed discontinuation symptoms and taper duration details are not supported by the label excerpt (especially 5.6 and 2.1).
Suggested Improvement
Restrict indication statements to the label-supported indications (e.g., adjunctive therapy for partial-onset seizures; fibromyalgia; neuropathic pain conditions) and align discontinuation guidance to label language: taper gradually over a minimum of 1 week and limit listed discontinuation symptoms to those explicitly named in 5.6 (insomnia, nausea, headache, anxiety, hyperhidrosis, diarrhea) within the provided excerpt.